EBUS-TBNA in Extrathoracic Malignancies: Diagnostic and Prognostic Implications

Martín-Deleon, Roberto; Solarat, Belen; Moisés, Jorge; Lucena, Carmen M.; Fontana, Ainhoa; Marrades, Ramón M.; Agustı́, Carles

doi:10.1007/s00408-022-00584-5

Cited by 5 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EBUS-TBNA involves transbronchial transmural needle aspiration guided by ultrasound bronchoscope for puncture sampling as a prevalent method of lung disease examination. Nevertheless, this method has limitations; for instance, when the focus diameter is small, it will be challenging to position and clip the tissue accurately, which will result in missed diagnoses and misdiagnosis (15). The study manifested that the diagnostic accuracy of EBUS-TBNA examination for LC is 60.67%, which is slightly lower than the result of a previous study (16).…”

Section: Discussionmentioning

confidence: 69%

Analysis of variation of serum CEA, SCC, CYFRA21-1 in patients with lung cancer and their diagnostic value with EBUS-TBNA

Du,

Wen,

Huang

2024

J Med Biochemistry

View full text Add to dashboard Cite

Objective: To explore the variation of serum carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1) and squamous cell carcinoma (SCC) antigen in patients with lung cancer (LC) and their diagnostic value with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). Methods: Selection of 150 patients with suspected lung malignant lesions as the research objects was to analyze the diagnostic value of serum tumor marker test and EBUS-TBNA joint detection for LC. Results: The AUC of joint examination to diagnose LC and identify pathological types of LC was elevated vs. alone detection of each index. Conclusions: Serum CYFRA21-1, SCC and CEA conjugating with EBUS-TBNA are provided with diagnostic value for LC and identified value for pathological types of LC.

show abstract

Section: Discussionmentioning

confidence: 69%

Analysis of variation of serum CEA, SCC, CYFRA21-1 in patients with lung cancer and their diagnostic value with EBUS-TBNA

Du,

Wen,

Huang

2024

J Med Biochemistry

View full text Add to dashboard Cite

show abstract

“…6 Moreover, studies revealed that the sensitivity of EBUS-TBNA for diagnosing intrathoracic metastases from extrapulmonary malignancies ranged from 83.3 to 93.3%. [27][28][29][30] Nonetheless, limited emphasis has been placed on the safety and accuracy of EBUS-TBNA for diagnosing previously treated extrathoracic malignancies, especially HNCs. In the present study, the diagnostic sensitivity of EBUS-TBNA in diagnosing intrathoracic metastases after HNC treatment was 88.2%, comparable with the literature.…”

Section: Discussionmentioning

confidence: 99%

“…A multicenter randomized controlled trial on the diagnostic value of EBUS‐TBNA for lung cancer reported a sensitivity, negative predictive value, and accuracy of 92%, 90%, and 95%, respectively 6 . Moreover, studies revealed that the sensitivity of EBUS‐TBNA for diagnosing intrathoracic metastases from extrapulmonary malignancies ranged from 83.3 to 93.3% 27–30 . Nonetheless, limited emphasis has been placed on the safety and accuracy of EBUS‐TBNA for diagnosing previously treated extrathoracic malignancies, especially HNCs.…”

Section: Discussionmentioning

confidence: 99%

The Diagnostic and Prognostic Value of EBUS‐TBNA for Intrathoracic Metastasis in Previously Treated Patients With Head and Neck Cancer

Zhang

Bao

et al. 2023

J of Ultrasound Medicine

View full text Add to dashboard Cite

ObjectiveThe present study assessed the diagnostic and prognostic significance of endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) for suspected intrathoracic metastasis after HNC treatment.MethodsA retrospective analysis was conducted on 75 patients with a prior history of head and neck cancer treatment who underwent EBUS‐TBNA for suspected intrathoracic metastases between March 2012 and December 2021.ResultsA total of 126 targeted lesions, including 107 mediastinal/hilar lymph nodes and 19 intrapulmonary/mediastinal masses, were sampled. The metastatic head and neck cancer (HNC) cases detected by EBUS‐TBNA consisted of nasopharyngeal carcinoma (n = 24), oropharyngeal carcinoma (n = 3), hypopharynx carcinoma (n = 6), laryngeal carcinoma (n = 6), and oral cavity carcinoma (n = 6). Cases with negative EBUS‐TBNA results consisted of tuberculosis (n = 9), sarcoidosis (n = 3), anthracosis (n = 9), and reactive lymphadenitis (n = 9). Six false‐negative cases were found among the 75 patients with suspected intrathoracic metastases. The diagnostic sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of the EBUS‐TBNA procedure for metastatic HNC were 88.2, 100.0, 100.0, 80, and 92.0%, respectively. The diagnosis of HNC intrathoracic metastasis by EBUS‐TBNA correlated with an adverse prognosis in terms of overall survival (OS) (P = .008). The log‐rank univariate analysis and Cox regression multivariate analysis results indicated that the detection of metastatic HNC through EBUS‐TBNA was a significant independent prognostic factor for patients with HNC who had received prior treatment.ConclusionsEndobronchial ultrasound‐guided transbronchial needle aspiration is a safe, effective, and minimally invasive procedure for assessing suspected intrathoracic metastasis in HNC patients after treatment. The intrathoracic metastasis detected by EBUS‐TBNA has crucial prognostic significance in previously treated HNC patients.

show abstract

“…In patients with extrathoracic malignancies (ETM), hilar, and mediastinal lymph node (MLN) enlargement raise the suspicion of metastasis. However, MLN may also be due to benign conditions like infections, or granulomatous inflammation 1–3 …”

Section: Introductionmentioning

confidence: 99%

Importance of mediastinal granulomatous/sarcoid‐like lymphadenopathy in extrathoracic malignancies

Erol,

Kaya,

Arslan

et al. 2024

Diagnostic Cytopathology

View full text Add to dashboard Cite

BackgroundIn patients with extrathoracic malignancies (ETM), granulomatous lymph adenopathy called sarcoid‐like reactions (SLR) can be seen in the regional or draining lymph nodes. We hypothesized that SLR may be a sign of imminent metastasis and investigated the clinical course and rate of recurrence in patients with ETM and granulomatous mediastinal lymphadenopathy (MLN).MethodsIn this retrospective observational study, we reviewed the medical files of patients with known ETM and who underwent EBUS‐TBNA for initial staging or detection of recurrence from 2011 to 2023. Patients with granulomatous MLN were included.ResultsForty‐one patients (29 female) enrolled in the study. Breast and colorectal carcinomas were the most common malignancies. A total of 81 lymph nodes were sampled. The final diagnosis of patients was five sarcoidosis, one tuberculosis, one second primary, one drug reaction, and 33 SLR. Among patients with SLR, in one patient lymph nodes progressed during the follow‐up and were accepted as false‐negative without confirmatory biopsy. The negative predictive value (NPV) of granulomatous MLN for metastasis was 97.05%.ConclusionGranulomatous MLN may be due to tuberculosis, drug reaction, sarcoidosis, or SLR in patients with ETM. SLR has a high NPV in patients with ETM. Follow‐up imaging rather than confirmatory biopsy is reasonable in these patients.

show abstract

EBUS-TBNA in Extrathoracic Malignancies: Diagnostic and Prognostic Implications

Cited by 5 publications

References 24 publications

Analysis of variation of serum CEA, SCC, CYFRA21-1 in patients with lung cancer and their diagnostic value with EBUS-TBNA

Analysis of variation of serum CEA, SCC, CYFRA21-1 in patients with lung cancer and their diagnostic value with EBUS-TBNA

The Diagnostic and Prognostic Value of EBUS‐TBNA for Intrathoracic Metastasis in Previously Treated Patients With Head and Neck Cancer

Importance of mediastinal granulomatous/sarcoid‐like lymphadenopathy in extrathoracic malignancies

Contact Info

Product

Resources

About